{"transactions":[{"id":4626540,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626539,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626538,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626537,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626536,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626535,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626534,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626533,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626532,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626531,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor."}],"balance_after":0,"derivative":{"exercise_price":28.14,"expiration_date":"2028-02-12","underlying":"Ordinary Shares","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626530,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":4626529,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:29:49.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74980,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001589602-26-000005","document":"form4-09252026_120944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000158960226000005/form4-09252026_120944.xml","form_type":"4"}},{"id":725249,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:23:23.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":22714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":22714,"derivative":{"exercise_price":8.05,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":22714},"source":{"system":"sec-edgar","filing":"0001628280-26-045788","document":"wk-form4_1782505401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000162828026045788/wk-form4_1782505401.xml","form_type":"4"}},{"id":725248,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T20:23:23.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":15527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant,  subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":41572,"source":{"system":"sec-edgar","filing":"0001628280-26-045788","document":"wk-form4_1782505401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000162828026045788/wk-form4_1782505401.xml","form_type":"4"}},{"id":735843,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:40:59.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001589602-26-000002","document":"form4-06172026_010655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000158960226000002/form4-06172026_010655.xml","form_type":"4"}},{"id":735842,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:40:59.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80989,"source":{"system":"sec-edgar","filing":"0001589602-26-000002","document":"form4-06172026_010655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000158960226000002/form4-06172026_010655.xml","form_type":"4"}},{"id":1099911,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-28T01:18:23.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":23105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":23105,"derivative":{"exercise_price":7.8,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":23105},"source":{"system":"sec-edgar","filing":"0001655759-25-000124","document":"wk-form4_1751073498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575925000124/wk-form4_1751073498.xml","form_type":"4"}},{"id":1099910,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-28T01:18:23.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders,  subject to the reporting person's continued service with the Issuer on the vesting date."}],"balance_after":26045,"source":{"system":"sec-edgar","filing":"0001655759-25-000124","document":"wk-form4_1751073498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575925000124/wk-form4_1751073498.xml","form_type":"4"}},{"id":1138652,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-21T23:00:30.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":24258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":24258,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001415889-25-013997","document":"form4-05212025_110526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588925013997/form4-05212025_110526.xml","form_type":"4"}},{"id":1138651,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-21T23:00:30.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":10649,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":74980,"source":{"system":"sec-edgar","filing":"0001415889-25-013997","document":"form4-05212025_110526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588925013997/form4-05212025_110526.xml","form_type":"4"}},{"id":1469030,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-06-26T20:42:08.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":5994,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":292923,"derivative":{"underlying":"Common Shares","underlying_shares":5994},"source":{"system":"sec-edgar","filing":"0001070235-24-000089","document":"wk-form4_1719434521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023524000089/wk-form4_1719434521.xml","form_type":"4"}},{"id":1493293,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-06-04T20:29:11.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17763,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":286929,"derivative":{"underlying":"Common Shares","underlying_shares":17763},"source":{"system":"sec-edgar","filing":"0001070235-24-000080","document":"wk-form4_1717532942.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023524000080/wk-form4_1717532942.xml","form_type":"4"}},{"id":1496335,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T21:50:10.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":9070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":9070,"derivative":{"exercise_price":33.9,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":9070},"source":{"system":"sec-edgar","filing":"0001655759-24-000080","document":"wk-form4_1717192202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575924000080/wk-form4_1717192202.xml","form_type":"4"}},{"id":1496334,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-31T21:50:10.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":5899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":10020,"source":{"system":"sec-edgar","filing":"0001655759-24-000080","document":"wk-form4_1717192202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575924000080/wk-form4_1717192202.xml","form_type":"4"}},{"id":1520369,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-10T22:01:01.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":23576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":23576,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001415889-24-012906","document":"form4-05102024_100555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588924012906/form4-05102024_100555.xml","form_type":"4"}},{"id":1520368,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-05-10T22:01:01.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":10537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64331,"source":{"system":"sec-edgar","filing":"0001415889-24-012906","document":"form4-05102024_100555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588924012906/form4-05102024_100555.xml","form_type":"4"}},{"id":1546809,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:27.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-010430","document":"form4-04052024_040417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010430/form4-04052024_040417.xml","form_type":"4"}},{"id":1546808,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:27.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010430","document":"form4-04052024_040417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010430/form4-04052024_040417.xml","form_type":"4"}},{"id":1546807,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:27.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001415889-24-010430","document":"form4-04052024_040417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010430/form4-04052024_040417.xml","form_type":"4"}},{"id":1546806,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T16:55:27.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60751,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was cancelled  pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for one non-transferable contingent value right (\"CVR\") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":5.63,"expiration_date":"2030-08-22","underlying":"Common Stock","underlying_shares":60751},"source":{"system":"sec-edgar","filing":"0001415889-24-010430","document":"form4-04052024_040417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000141588924010430/form4-04052024_040417.xml","form_type":"4"}},{"id":1604285,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2024-03-04T23:40:33.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":17763,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":269166,"derivative":{"underlying":"Common Shares","underlying_shares":17763},"source":{"system":"sec-edgar","filing":"0001070235-24-000050","document":"wk-form4_1709595620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023524000050/wk-form4_1709595620.xml","form_type":"4"}},{"id":1724336,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-12-04T21:34:26.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":13554,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":251403,"derivative":{"underlying":"Common Shares","underlying_shares":13554},"source":{"system":"sec-edgar","filing":"0001070235-23-000156","document":"wk-form4_1701725654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023523000156/wk-form4_1701725654.xml","form_type":"4"}},{"id":1791237,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-09-01T20:29:07.000Z","date":"2023-08-31","kind":"grant","planned":false,"acquired":true,"shares":8953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":237849,"derivative":{"underlying":"Common Shares","underlying_shares":8953},"source":{"system":"sec-edgar","filing":"0001070235-23-000117","document":"wk-form4_1693600139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023523000117/wk-form4_1693600139.xml","form_type":"4"}},{"id":1791737,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T18:52:05.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.98,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-047832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919123047832/doc4.xml","form_type":"4"}},{"id":1791736,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T18:52:05.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":1.87,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-047832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919123047832/doc4.xml","form_type":"4"}},{"id":1848851,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T21:28:43.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":12787,"derivative":{"exercise_price":30.33,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":12787},"source":{"system":"sec-edgar","filing":"0001655759-23-000067","document":"wk-form4_1687296513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575923000067/wk-form4_1687296513.xml","form_type":"4"}},{"id":1848850,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T21:28:43.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":4121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":4121,"source":{"system":"sec-edgar","filing":"0001655759-23-000067","document":"wk-form4_1687296513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000165575923000067/wk-form4_1687296513.xml","form_type":"4"}},{"id":1857313,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-13T18:31:52.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 12, 2023 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":25000,"derivative":{"exercise_price":3.48,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-036866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919123036866/doc4.xml","form_type":"4"}},{"id":1869092,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T20:13:23.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continued service to the Issuer on each applicable vesting date, the option vests as to 1/12 of the total award on each monthly anniversary of the Grant Date; provided, however, that notwithstanding the monthly vesting schedule, the options shall vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the next annual meeting of the stockholders."}],"balance_after":37500,"derivative":{"exercise_price":1.87,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-23-033683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919123033683/doc4.xml","form_type":"4"}},{"id":1872465,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-06-01T20:36:29.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":9259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":228896,"derivative":{"underlying":"Common Shares","underlying_shares":9259},"source":{"system":"sec-edgar","filing":"0001070235-23-000097","document":"wk-form4_1685651773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023523000097/wk-form4_1685651773.xml","form_type":"4"}},{"id":1904038,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-04T22:33:56.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":22044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":22044,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001415889-23-007372","document":"form4-05042023_100550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923007372/form4-05042023_100550.xml","form_type":"4"}},{"id":1904037,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-04T22:33:56.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":9132,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":53794,"source":{"system":"sec-edgar","filing":"0001415889-23-007372","document":"form4-05042023_100550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923007372/form4-05042023_100550.xml","form_type":"4"}},{"id":1984622,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2023-03-01T21:33:29.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":12736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":219637,"derivative":{"underlying":"Common Shares","underlying_shares":12736},"source":{"system":"sec-edgar","filing":"0001070235-23-000041","document":"wf-form4_167770639027562.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023523000041/wf-form4_167770639027562.xml","form_type":"4"}},{"id":2100378,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-12-01T21:36:52.000Z","date":"2022-11-30","kind":"grant","acquired":true,"shares":10353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":206901,"derivative":{"underlying":"Common Shares","underlying_shares":10353},"source":{"system":"sec-edgar","filing":"0001070235-22-000162","document":"wf-form4_166993059812044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023522000162/wf-form4_166993059812044.xml","form_type":"4"}},{"id":2156945,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-16T20:06:42.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in substantially equal monthly installments over three years, subject to a continued service relationship."}],"balance_after":75000,"derivative":{"exercise_price":2.98,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-050297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919122050297/doc4.xml","form_type":"4"}},{"id":2169247,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-09-01T20:35:28.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":8653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":196548,"derivative":{"underlying":"Common Shares","underlying_shares":8653},"source":{"system":"sec-edgar","filing":"0001070235-22-000126","document":"wf-form4_166206451390449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023522000126/wf-form4_166206451390449.xml","form_type":"4"}},{"id":2224911,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T00:00:35.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":10192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":10192,"derivative":{"exercise_price":36.79,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10192},"source":{"system":"sec-edgar","filing":"0001209191-22-038556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919122038556/doc4.xml","form_type":"4"}},{"id":2231538,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-15T17:00:25.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 13, 2022 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":8.38,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-22-037017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919122037017/doc4.xml","form_type":"4"}},{"id":2249973,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-06-01T20:41:00.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":8859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":187895,"derivative":{"underlying":"Common Shares","underlying_shares":8859},"source":{"system":"sec-edgar","filing":"0001070235-22-000099","document":"wf-form4_165411603717066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023522000099/wf-form4_165411603717066.xml","form_type":"4"}},{"id":2288571,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2022-04-29T00:50:34.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":28000,"derivative":{"exercise_price":10.15,"expiration_date":"2032-04-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001415889-22-004326","document":"form4-04282022_050440.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922004326/form4-04282022_050440.xml","form_type":"4"}},{"id":2288570,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-04-29T00:50:34.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":9852,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44662,"source":{"system":"sec-edgar","filing":"0001415889-22-004326","document":"form4-04282022_050440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588922004326/form4-04282022_050440.xml","form_type":"4"}},{"id":2366418,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2022-03-01T21:35:26.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":7758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":179036,"derivative":{"underlying":"Common Shares","underlying_shares":7758},"source":{"system":"sec-edgar","filing":"0001070235-22-000040","document":"wf-form4_164617049375419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023522000040/wf-form4_164617049375419.xml","form_type":"4"}},{"id":2489397,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-12-02T21:32:16.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":5547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":171278,"derivative":{"underlying":"Common Shares","underlying_shares":5547},"source":{"system":"sec-edgar","filing":"0001070235-21-000139","document":"wf-form4_163848071387820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023521000139/wf-form4_163848071387820.xml","form_type":"4"}},{"id":2584056,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-09-01T20:37:12.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":4694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":165731,"derivative":{"underlying":"Common Shares","underlying_shares":4694},"source":{"system":"sec-edgar","filing":"0001070235-21-000092","document":"wf-form4_163052861647615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023521000092/wf-form4_163052861647615.xml","form_type":"4"}},{"id":2670333,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T19:15:42.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares underlying the Option vest and become exercisable on a monthly basis starting July 11, 2021 (the Vest Base Date) and thereafter on the same day of the month as the Vest Base Date or if earlier, the day immediately before the date of the next Annual Meeting of Stockholders that occurs after the Vest Base Date."}],"balance_after":20250,"derivative":{"exercise_price":24.46,"expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0001209191-21-040403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1797768/000120919121040403/doc4.xml","form_type":"4"}},{"id":2673330,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T00:00:51.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":7511,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 8, 2021. The shares underlying the award shall vest in full on June 8, 2022 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":7511,"derivative":{"exercise_price":78.53,"expiration_date":"2021-06-07","underlying":"Common Stock","underlying_shares":7511},"source":{"system":"sec-edgar","filing":"0001209191-21-039679","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919121039679/doc4.xml","form_type":"4"}},{"id":2689632,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-06-01T20:41:22.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":5560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":161037,"derivative":{"underlying":"Common Shares","underlying_shares":5560},"source":{"system":"sec-edgar","filing":"0001070235-21-000057","document":"wf-form4_162258003632793.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023521000057/wf-form4_162258003632793.xml","form_type":"4"}},{"id":2735504,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-04-29T22:11:47.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":20.35,"expiration_date":"2031-04-26","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-21-004696","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021004696/edgar.xml","form_type":"4"}},{"id":2735503,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-29T22:11:47.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":9828,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":34810,"source":{"system":"sec-edgar","filing":"0001179110-21-004696","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911021004696/edgar.xml","form_type":"4"}},{"id":2821925,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2021-03-02T21:29:57.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":5245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":155477,"derivative":{"underlying":"Common Shares","underlying_shares":5245},"source":{"system":"sec-edgar","filing":"0001070235-21-000020","document":"wf-form4_161472057940141.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023521000020/wf-form4_161472057940141.xml","form_type":"4"}},{"id":2961412,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-12-02T21:35:02.000Z","date":"2020-11-30","kind":"grant","acquired":true,"shares":8823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":150232,"derivative":{"underlying":"Common Shares","underlying_shares":8823},"source":{"system":"sec-edgar","filing":"0001070235-20-000151","document":"wf-form4_160694488939042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023520000151/wf-form4_160694488939042.xml","form_type":"4"}},{"id":3041621,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-09-02T20:36:43.000Z","date":"2020-08-31","kind":"grant","acquired":true,"shares":9927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":141409,"derivative":{"underlying":"Common Shares","underlying_shares":9927},"source":{"system":"sec-edgar","filing":"0001070235-20-000090","document":"wf-form4_159907898542769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023520000090/wf-form4_159907898542769.xml","form_type":"4"}},{"id":3121630,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T01:00:15.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":12000,"derivative":{"exercise_price":33.57,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-034586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919120034586/doc4.xml","form_type":"4"}},{"id":3129484,"issuer":{"id":3966,"kind":"organization","name":"BLACKBERRY Ltd","symbol":"BB"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Share Unit","published_at":"2020-06-01T20:52:04.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":10547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Deferred Share Unit (\"DSU\") is the economic equivalent of one common share. The DSUs become payable, in cash or common shares or a combination of the two, at the discretion of BlackBerry Limited (\"BlackBerry\") following cessation of the reporting person's service as a director of BlackBerry."}],"balance_after":131482,"derivative":{"underlying":"Common Shares","underlying_shares":10547},"source":{"system":"sec-edgar","filing":"0001070235-20-000052","document":"wf-form4_159104470631991.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070235/000107023520000052/wf-form4_159104470631991.xml","form_type":"4"}},{"id":3166263,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2020-04-30T22:50:44.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":30.14,"expiration_date":"2030-04-27","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-20-005293","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020005293/edgar.xml","form_type":"4"}},{"id":3166262,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-04-30T22:50:44.000Z","date":"2020-04-28","kind":"grant","acquired":true,"shares":6635,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24982,"source":{"system":"sec-edgar","filing":"0001179110-20-005293","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911020005293/edgar.xml","form_type":"4"}},{"id":3360785,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T21:38:18.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":25846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on November 20, 2019. The shares underlying the award shall vest in equal monthly installments through November 20, 2022."}],"balance_after":25846,"derivative":{"exercise_price":34.07,"expiration_date":"2029-11-19","underlying":"Common Stock","underlying_shares":25846},"source":{"system":"sec-edgar","filing":"0001209191-19-057808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589602/000120919119057808/doc4.xml","form_type":"4"}},{"id":3541941,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2019-05-02T22:11:13.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":23.85,"expiration_date":"2029-04-29","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-19-005451","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019005451/edgar.xml","form_type":"4"}},{"id":3541940,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-02T22:11:13.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":8385,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18347,"source":{"system":"sec-edgar","filing":"0001179110-19-005451","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911019005451/edgar.xml","form_type":"4"}},{"id":3946845,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2018-05-03T22:18:45.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":6000,"derivative":{"exercise_price":24.43,"expiration_date":"2028-04-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001179110-18-006195","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018006195/edgar.xml","form_type":"4"}},{"id":3946844,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-03T22:18:45.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":8186,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9962,"source":{"system":"sec-edgar","filing":"0001179110-18-006195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018006195/edgar.xml","form_type":"4"}},{"id":4054202,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2018-02-15T22:17:44.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest monthly over three months of service from the date of grant and in full on the date of the Company's 2018 annual meeting of shareholders."}],"balance_after":1500,"derivative":{"exercise_price":28.14,"expiration_date":"2028-02-12","underlying":"Ordinary Shares","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001179110-18-002191","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018002191/edgar.xml","form_type":"4"}},{"id":4054201,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2018-02-15T22:17:44.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests monthly over 24 months of service from the date of grant."}],"balance_after":12000,"derivative":{"exercise_price":28.14,"expiration_date":"2028-02-12","underlying":"Ordinary Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001179110-18-002191","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018002191/edgar.xml","form_type":"4"}},{"id":4054200,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":35099,"kind":"person","name":"Smaldone Alsup Laurie","position":1,"cik":"0001589602","reported_name":"Smaldone Alsup Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-02-15T22:17:44.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":1776,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1776,"source":{"system":"sec-edgar","filing":"0001179110-18-002191","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000117911018002191/edgar.xml","form_type":"4"}}]}